Connect with us

Press Releases

Marcolin Group Enters a Partnership with Positive Luxury

This is by sponsoring the inaugural Positive Luxury Awards 2020.

mm

Published

on

(PRESS RELEASE) Marcolin Group, a worldwide leading company in the eyewear industry, announces its partnership with Positive Luxury for their first edition of the Positive Luxury Awards. The ceremony is taking place in London on the 25th of February 2020 and the Group will present the Innovation of the Year Award.

Founded in 2011, Positive Luxury is an award-winning sustainability platform that connects luxury brands with people working towards a better future through the unique Butterfly Mark, a symbol of trust earned by brands that have adopted sustainability as a key business principle.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The Positive Luxury Awards 2020 is a global celebration of sustainability and innovation within the luxury industry, featuring a variety of categories recognizing companies or individuals affecting positive change in businesses and the global community.

Marcolin Group will sponsor the Innovation of the Year Award which identifies true innovators taking an entirely new approach to their service, product, technology or business model, improving their social or environmental performance while also offering large scale improvements internally and externally.

The evening’s winners will be selected by a special jury consisting of 12 global business leaders, including American-British model and activist, Arizona Muse, United Nations officer, Simone Cipriani, author of The New Green Consumer Guide, Julia Hailes, business writer and advisor, John Elkington, author and British Fashion Council’s Advisory Board member, Frances Corner, model, actress and activist, Amber Valletta, Parsons School of Design Dean of Fashion, Burak Cakmak, communications consultant and writer, Emma Young, journalist and author, Isabelle Lefort, Business for Social

Responsibility Managing Director, Elisa Niemtzow, and Imagine Co-founder and International Chamber of Commerce Chair, Paul Polman.

Advertisement

Massimo Renon, Marcolin Group CEO, affirmed: “Marcolin Group is the first international eyewear company collaborating with Positive Luxury. We will demonstrate to our partners and consumers that we are tracing a new path in the sustainability. Our relentless pursuit of innovation and experimentation has led Marcolin Group to become the first sponsor for The Positive Luxury Innovation of the Year Award”.

Diana Verde Nieto, Co-Founder and CEO of Positive Luxury, stated: “Marcolin Group’s commitment to craftsmanship and quality has helped them build an unparalleled reputation in the eyewear industry. We are proud to work with them and have their support for the Positive Luxury Awards 2020, more specifically, the Innovation of the Year Award”.

Advertisement

SPONSORED VIDEO

SPONSORED BY KENMARK

Jump In — the Water’s Fine!

With a salute to summer’s shimmery, mermaid colors and warm weather-loving shades, Kenmark Eyewear celebrates this summer’s Aloha spirit with eyewear from Vera Wang, Kensie, Zac Posen and the Original Penguin Collection!

Promoted Headlines

Press Releases

OGI Announces the Appointment of David Duralde as Chief Creative Officer

He will not only lead creative development but will also serve as partner.

mm

Published

on

(PRESS RELEASE) OGI Eyewear, a member of The Optical Foundry, announces the appointment of David Duralde as chief creative officer. Duralde has joined the company not only to lead creative development but also as a partner.

Duralde’s distinguished optical career is marked by extensive experience both with licensed and independent brands, including his most recent role as Chief Creative Officer at Kenmark Eyewear. “I am very excited about the opportunity to redefine and reinvigorate the niche independent brands in the OGI portfolio of products and provide a consistent, compelling story to the brands. I can’t wait to get started with the OGI
Eyewear product and marketing teams to connect deeply with our loyal customers, create frames that light up many more faces and help independent practices thrive and shine in this vigorously changing market.” said Duralde.

Robert Rich, CEO of OGI, notes, “David is exactly the right person to lead us in the revitalization of our brand portfolio. Despite a solid market position, OGI and its family of brands will benefit from an injection of fresh ideas and design innovations that will expand our leading role in the realm of affordable luxury frames.”

Rich adds, “This is a homecoming of sorts for David, having begun his formative optical design training at l.a.Eyeworks, another member of the Optical Foundry.”

Continue Reading

Press Releases

First US Patient Gets Wireless Retinal Device Implant

It’s aimed at restoring partial sight to patients with advanced age-related macular degeneration.

mm

Published

on

(PRESS RELEASE) PITTSBURGH – UPMC has implanted the first patient in the U.S. with a new wireless retinal device as part of a clinical trial aimed at restoring partial sight to patients with advanced age-related macular degeneration.

“Vision research has advanced dramatically in the recent past and UPMC is at the forefront of this revolution. This is the first of many such breakthroughs led by UPMC and Pitt that will benefit patients with vision loss in our community and around the world,” said José-Alain Sahel, MD, director of the UPMC Eye Center, Eye and Ear Foundation chair of ophthalmology and distinguished professor at the University of Pittsburgh School of Medicine who initiated the trial at UPMC. “We are proud to be the first center in the United States to test this next generation retinal implant that could help treat an incurable disease like AMD.”

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The system, called PRIMA, is designed to restore sight in patients blinded by retinal degeneration. It consists of a 2 millimeter-by-2 millimeter, 30-micron thick miniaturized wireless photovoltaic chip placed under the damaged retina. It works in tandem with augmented reality glasses that have a built-in miniaturized camera and infrared projector.

The chip acts like a tiny artificial retina, made up of 378 tiny electrodes that convert infrared light from the glasses to electrical signals that are carried by the optic nerve to the brain. After receiving the implant, patients undergo an intensive rehabilitation program that trains their brains to understand and interpret the signals from the implant in combination with their remaining natural vision. Compared to earlier-generation implants, PRIMA is wireless and has significantly more electrodes, which allows for the transmission of more visual information.

“This is an incredibly exciting first for us at UPMC and I’m honored to be a part of it,” said Joseph Martel, MD, the implanting surgeon at the UPMC Eye Center and the Pitt School of Medicine, and the principal investigator of the trial at UPMC. “I’m grateful to our patients who have volunteered to participate in this trial, without whom this would not be possible.”

AMD is the leading cause of vision loss in people older than 50. Today, it affects approximately 14 million people in the United States, and the prevalence is expected to rise as the baby boomers age. As AMD progresses, the center of vision becomes increasingly blurry. “Atrophic” AMD, which accounts for a large proportion of advanced cases, has no curative treatment available.

The UPMC feasibility trial is running in parallel with the first-in-human trial in France, which involves five patients with advanced AMD, who now have been followed for more than a year. The 12-month results from the French study demonstrated the ability of most patients to identify sequences of letters and there were no device-related serious adverse effects.

“We are working with a great sense of urgency because the aging population of the United States, especially the western Pennsylvania region we live in, will see a significant rise in the number of patients at risk for vision loss through diseases like age-related macular degeneration, glaucoma and vascular eye disease, as well as earlier onset genetic conditions such as retinitis pigmentosa,” said Sahel. “This is why our physicians and researchers at UPMC and Pitt, in collaboration with our U.S. and international colleagues — especially at the Paris Vision Institute at Sorbonne University — are taking a multi-pronged effort to treat and rehabilitate patients with vision impairments.”

In March 2019, UPMC broke ground on the UPMC Vision and Rehabilitation Tower at UPMC Mercy, which when completed, will provide advanced specialty clinical care and innovative programs for visually impaired patients. It also will be the home for the vision research program at Pitt and UPMC.

The PRIMA implant was invented by Daniel Palanker, professor of ophthalmology at Stanford University, and licensed and developed by Pixium Vision, a spin-off from the Paris Vision Institute. Sahel is a co-founder of Pixium and holds shares in the company.

Continue Reading

Press Releases

There Might Be a Faster and Cheaper Way to Test for Myopia

The research comes from Flinders University in Australia.

mm

Published

on

(PRESS RELEASE) Myopia could become significantly easier to assess, according to a group of scientists.

Progressive research at Flinders University in Australia has identified a new method to measure how it affects the eye, a new article in PLOS ONE reveals.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The work was based on testing of 70 volunteers, with the Flinders ophthalmology and medical device research institute experts taking a novel approach with optical coherence tomography (OCT), a device already available in most optometric and all ophthalmic practices.

“Our work uses the OCT and finds irregularities at this scale that correlate with the size of the eye, and therefore the degree of myopia,” says eye specialist Dr. Stewart Lake, from Flinders University.

“This may help monitor, measure, and explore the effects of myopia and how it leads to vision loss,” he says, adding that further development could make the system suitable for use in regular clinical practice.

Prior research elsewhere with MRI scanning has demonstrated large scale irregularities in the eyeball in highly myopic eyes.

OCT can sample the shape of the eye on a much smaller scale than MRI. The OCT testing will be far cheaper, is more readily available and repeatable as a test, researchers say in the article.

Myopia (short or near-sightedness) is for many an inconvenience requiring glasses or contact lens to correct. However, globally it is an epidemic and a major cause of vision loss and sometimes blindness.

Myopia is defined practically by the strength of lens required to correct eyesight. It was already known that myopia relates strongly to the size/length of the eyeball.

Global estimates forecast up to 5 billion people will have myopia and 1 billion people could suffer with high myopia by 2050, placing a significant burden on health systems to manage and prevent myopia-related ocular complications and vision loss.

This seven-fold increase, between 2000 and 2050, would make myopia the leading cause of permanent blindness worldwide.

High myopia increases the risk of pathological ocular changes such as cataract, glaucoma, retinal detachment and myopic macular degeneration, all of which cause irreversible vision loss

Continue Reading

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Instagram

This error message is only visible to WordPress admins

Error: API requests are being delayed for this account. New posts will not be retrieved.

There may be an issue with the Instagram Access Token that you are using. Your server might also be unable to connect to Instagram at this time.

Error: No posts found.

Make sure this account has posts available on instagram.com.

Error: admin-ajax.php test was not successful. Some features may not be available.

Please visit this page to troubleshoot.

Most Popular